<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85724">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01968850</url>
  </required_header>
  <id_info>
    <org_study_id>CTNPT 021</org_study_id>
    <nct_id>NCT01968850</nct_id>
  </id_info>
  <brief_title>Bone Antiresorptive Therapy With Antiretroviral Initiation (BATARI) Pilot Trial</brief_title>
  <acronym>BATARI</acronym>
  <official_title>Bone Antiresorptive Therapy With Antiretroviral Initiation (BATARI) Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Michael's Hospital, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CIHR Canadian HIV Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Michael's Hospital, Toronto</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two-site, three-arm, open-label, pilot randomized controlled trial of bone
      anti-resorptive therapy during ART initiation in HIV-infected adults.  Thirty (30)
      treatment-naïve HIV-infected adults initiating eligible first-line ART regimens will be
      randomized in a 1:1:1 fashion to one of the following three arms:

        1. no bone anti-resorptive therapy (standard of care)

        2. concomitant initiation of a 24 week course of co-formulated alendronate/vitamin D;

        3. a 24 week delay in initiation of a 24 week course of alendronate/vitamin D

      Assessments (including clinical evaluation, questionnaires, adherence, basic laboratory
      evaluation, and BMD measurement) will be performed at baseline, 24 and 48 weeks.  The
      primary objective will involve calculation of σ and ρ using all data; δ will be estimated by
      comparing the two alendronate arms pooled to the no-treatment arm.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Percentage changes in BMD at a) the lumbar spine and b) proximal femur</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary analysis will compare the percentage changes in BMD for the two alendronate/vitamin D arms pooled against the control arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The proportion of patients who are eligible and who consent to participate will be calculated, and the timeliness (rate) of enrollment will be described, to further inform the feasibility of a larger randomized controlled trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Using standardized questions, participants will be asked about the acceptability of the alendronate therapy (including the experience of pill-taking and the weekly schedule)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety/Tolerability</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>As per Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Adherence with anti-resorptive therapy will be assessed by pill count and questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Biomarkers</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Two bone biomarkers will be assessed: cross-linked carboxyterminal-telopeptide (CTX) and aminoterminal propeptide of type 1 collagen (P1NP).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>no bone anti-resorptive therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>(standard of care)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>24-week tx of alendronate/vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concomitant initiation of a 24 week course of co-formulated alendronate/vitamin D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed 24-week tx of alendronate/vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a 24 week delay in initiation of a 24 week course of alendronate/vitamin D</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alendronate/vitamin D</intervention_name>
    <description>once weekly 70mg oral dose of alendronate co-formulated with 5600IU vitamin D3 (cholecalciferol) for 24 weeks.</description>
    <arm_group_label>24-week tx of alendronate/vitamin D</arm_group_label>
    <arm_group_label>Delayed 24-week tx of alendronate/vitamin D</arm_group_label>
    <other_name>Fosavance 70/56</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented HIV-1 infection

          -  Adult (aged &gt;18 years or as per local guidelines)

          -  Premenopausal, if female

          -  Antiretroviral-naïve

          -  Starting first-line ART including tenofovir/emtricitabine with either efavirenz
             (co-formulated as Atripla®) or elvitegravir, cobicistat (co-formulated as Stribild®)

          -  Low (&lt;10%) ten-year fracture risk as assessed by the FRAX score validated for
             Canadian populations

        Exclusion Criteria:

          -  Presence of established osteoporosis at baseline as determined by BMD measurement

          -  Prior or current use of any bone anti-resorptive therapy (eg. bisphosphonate,
             estrogens with the exception of oral contraceptive pills, etc.)

          -  Inability to communicate in English

          -  Creatinine clearance &lt;35 mL/min (using Cockcroft-Gault formula)

          -  Hypersensitivity to alendronate, other bisphosphonates, or any component of the
             formulation

          -  Hypocalcemia

          -  Abnormalities of the esophagus which delay esophageal emptying such as stricture or
             achalasia

          -  Inability to stand or sit upright for at least 30 minutes

          -  Pregnancy, active plans to become pregnant, or lactation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darrell Tan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Michael's Hospital, Toronto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Darrell Tan, MD</last_name>
    <phone>4168646060</phone>
    <phone_ext>5568</phone_ext>
    <email>darrell.tan@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Darrell Tan, MD</last_name>
      <phone>4168646060</phone>
      <phone_ext>77505</phone_ext>
      <email>darrell.tan@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Darrell Tan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sharon Walmsley, MD</last_name>
      <phone>4163403871</phone>
      <email>sharon.walmsley@uhn.com</email>
    </contact>
    <investigator>
      <last_name>Sharon Walmsley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 12, 2014</lastchanged_date>
  <firstreceived_date>October 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>HIV</keyword>
  <keyword>bone Mineral Density</keyword>
  <keyword>alendronate</keyword>
  <keyword>vitamin D</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
